Physician profile
Hesham Taha
NPI 1922067941
$7,772.56
in general payments reported to CMS, 2019-2025
37 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,674 · 2020: $1,134 · 2022: $266 · 2023: $917 · 2024: $412 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,081.60 | 2019-2025 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $916.37 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $478.22 | 2019-2024 | Pomalyst, Opdivo |
| Amgen INC. | $369.94 | 2019-2022 | |
| Janssen Biotech, INC. | $348.32 | 2019-2024 | Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $248.65 | 2023-2025 | Imfinzi, Lynparza |
| Emd Serono, INC. | $135.67 | 2019-2020 | |
| Daiichi Sankyo INC. | $125.98 | 2019-2024 | Enhertu |
| Gilead Sciences, INC. | $124.99 | 2024 | Trodelvy |
| Genmab U.S., INC. | $119.78 | 2023 | Tivdak |
| Mirati Therapeutics, INC. | $90.00 | 2023 | Krazati |
| Beigene USA, INC. | $77.88 | 2023 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $73.75 | 2019 | |
| Pfizer INC. | $55.00 | 2019 | |
| Genzyme Corporation | $50.00 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesham Taha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.